Atopic dermatitis (AD), commonly called eczema, is a chronic inflammatory skin condition that can cause persistent itching, dry skin, redness, rashes, and recurring flares. For people with moderate to severe atopic dermatitis that is not adequately controlled with topical treatment, biologic medicines can provide a targeted approach to reducing inflammation. A dermatologist can evaluate disease severity, previous treatment response, and individual health factors to determine whether biologic therapy is appropriate. Regular monitoring helps assess effectiveness and manage potential side effects.
Biologic therapies are medications designed to target specific immune pathways involved in atopic dermatitis.
They can help:
Biologics are generally considered when topical therapies and other appropriate treatments do not provide adequate disease control.
Several targeted biologic treatments are used for moderate to severe atopic dermatitis.
Dupilumab blocks signaling from interleukin-4 and interleukin-13, two important inflammatory pathways associated with type 2 inflammation.
It is used for eligible patients with moderate to severe atopic dermatitis and can significantly reduce itching and skin inflammation.
Some newer biologic therapies specifically target interleukin-13.
Examples include:
These treatments are designed to reduce inflammatory signaling associated with atopic dermatitis.
Biologic therapy may be considered when atopic dermatitis is moderate to severe and remains inadequately controlled despite appropriate treatment.
Healthcare providers may consider:
There is no single laboratory test that determines whether biologic treatment is appropriate.
Most atopic dermatitis biologics are administered as subcutaneous injections.
Depending on the medication, injections may be given at intervals ranging from every few weeks to longer maintenance intervals.
Some patients may administer medication at home after receiving appropriate instructions.
For eligible patients, biologic treatment may:
Individual responses vary, and treatment effectiveness is assessed over time.
Side effects vary by medication.
Potential reactions may include:
Serious reactions are uncommon but can occur. Healthcare providers discuss medication-specific risks before treatment begins.
Biologics generally do not mean that topical skin care becomes unnecessary.
Moisturizers, topical corticosteroids, topical calcineurin inhibitors, or other prescribed treatments may continue to be part of an overall management plan.
A dermatologist may adjust topical treatment as skin inflammation improves.
Before starting biologic therapy, a dermatologist typically reviews:
Photographs or standardized severity assessments may also be used to track improvement.
Regular follow-up helps determine whether the medication is providing sufficient benefit.
Monitoring may include:
Treatment may be continued, adjusted, or changed depending on the response.
Prompt medical evaluation may be appropriate when atopic dermatitis is accompanied by:
Skin infections can occur with severe eczema and may require additional treatment.
Biologic therapies have expanded treatment possibilities for people with moderate to severe atopic dermatitis. Treatments targeting IL-4, IL-13, and related inflammatory pathways can reduce itching and skin inflammation and improve quality of life for appropriately selected patients.